drugset / Trial / NCT06272812
A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.
Phase 2
Recruiting
5500 enrolled
International AIDS Vaccine Initiative
Biofabri, SLU · collabUniversidad de Zaragoza · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region.
Timeline
- Start
- 2025-02-19
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MTBVAC | Vaccine | 500000 unknown | Other |